Cerebrospinal fluid β2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor α receptors before and after treatment with lamivudine plus zidovudine or stavudine

Journal of Neuroimmunology

Volumn 102, Issue 2, 2000, Pages 216-221

  Enting, Roelien H ^a   Foudraine, Norbert A ^a,b   Lange, Joep M A ^a   Jurriaans, Suzanne ^a   Van Der Poll, Tom ^c   Weverling, Gerrit Jan ^a   Portegies, Peter ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MUNICIPAL HEALTH SERVICE   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

2 microglobulin; Antiviral therapy; Cerebrospinal fluid; HIV 1; Monocyte chemotactic protein 1; Soluble tumour necrosis factor receptors

Indexed keywords

BETA 2 MICROGLOBULIN; BIOCHEMICAL MARKER; LAMIVUDINE PLUS ZIDOVUDINE; MONOCYTE CHEMOTACTIC PROTEIN 1; STAVUDINE; TUMOR NECROSIS FACTOR RECEPTOR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE;

ARTICLE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ADULT; BLOOD; DRUG COMBINATION; MIDDLE AGED; SOLUBILITY;

ADULT; ANTI-HIV AGENTS; BETA 2-MICROGLOBULIN; CHEMOKINE CCL2; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SOLUBILITY; STAVUDINE; ZIDOVUDINE;

EID: 0033621627     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(99)00219-2     Document Type: Article

References (35)

1. An S.F., Scaravilli F. Early HIV-1 infection of the central nervous system. Arch. Anat. Cytol. Pathol. 45:1997;94-105.
2. Bilello S., Stellrecht K., Drusano G.L., Stein D.S. Soluble tumor necrosis factor-α receptor type II (sTNFαRII) correlates with human immunodeficiency virus (HIV) RNA copy number in HIV-infected patients. J. Infect. Dis. 173:1996;464-467.
3. Bisset L.R., Rothen M., Joller-Jemelka H.I., Dubs R.W., Grob P.J., Opravil M. Change in circulating levels of the chemokines macrophage inflammatory proteins 1α and 1β, RANTES, monocyte chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-infected individuals with indinavir. AIDS. 11:1997;485-491.
4. Brew B.J. Neurological efficacy of stavudine, zidovudine, and lamivudine. Lancet. 352:1998;402-403.
5. Brew B.J., Dunbar N., Pemberton L., Kaldor J. Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of β-2-microglobulin and neopterin. J. Infect. Dis. 174:1996;294-298.
6. Castejon, M., McCoig, C., McClernon, D., et al., 1998. Impact of treatment with zidovudine/lamivudine om abacavir on cerebrospinal fluid HIV-1 RNA and cytokine concentrations in HIV-1 infected children. Abstracts of the 38th ICAAC, San Diego, CA, USA.
7. Cinque P., Vago L., Mengozzi M.et al. Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS. 12:1998;1327-1332.
8. Conant K., Garzino-Demo A., Nath A.et al. Induction of monocyte chemoattractant protein-1 in HIV-1 TAT-stimulated astrocytes and elevation in AIDS dementia. Proc. Natl. Acad. Sci. U. S. A. 95:1998;3117-3121.
9. Elovaara E., Poutianen E., Lahdevirta J.et al. Zidovudine reduces intrathecal immunoactivation in patients with early human immunodeficiency virus type 1 infection. Arch. Neurol. 51:1994;943-950.
10. Enting R.H., Hoetelmans R.M.W., Lange J.M.A., Burger D.M., Beijnen J.H., Portegies P. Antiretroviral drugs and the central nervous system. AIDS. 12:1998;1941-1955.
11. Flore M., Mitchell J., Nelson R.et al. The Abbott IMx™ automated benchtop immunochemistry analyzer system. Clin. Chem. 34:1988;1726-1732.
12. Foudraine N.A., Hoetelmans R.M.W., Lange J.M.A.et al. Cerebrospinal fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet. 351:1998;1547-1551.
13. Foudraine N.A., Jurriaans S., Weverling G.J.et al. Plasma and cerebrospinal fluid HIV-RNA and drug levels after 48 weeks of follow up of patients treated with AZT/3TC or d4T/3TC with sequential addition of indinavir. AIDS. 12(Suppl. 4):1998;533.
14. Gisslen M., Chiodi F., Fuchs D.et al. Markers of immune stimulation in the cerebrospinal fluid during HIV infection: a longitudinal study. Scand. J. Infect. Dis. 26:1994;523-533.
15. Gisslen M., Norkrans G., Svennerholm B., Hagberg L. The effect on human immunodeficiency virus type I RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J. Infect. Dis. 175:1997;434-437.
16. Gisslen M., Norkrans G., Svennerholm B., Hagberg L. HIV-1 RNA detectable with ultrasensitive quantitative polymerase chain reaction in plasma but not in cerebrospinal fluid during combination treatment with zidovudine, lamivudine and indinavir. AIDS. 12:1998;114-115.
17. Godfried M.H., van der Poll T., Mulder J.W.et al. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 10:1995;531-539.
18. Godfried M.H., van der Poll T., Weverling G.J.et al. Soluble receptors for tumour necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection. J. Infect. Dis. 169:1994;739-745.
19. Janssen R.S., Nwanyanwu O.C., Selik R.M., Stehr-Green J.K. Epidemiology of human immunodeficiency virus encephalopathy in the United States. Neurology. 42:1992;1472-1476.
20. Kelder W., McArthur J.C., Nance-Sproson T., McClernon D., Griffin D.E. β-Chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann. Neurol. 44:1998;831-835.
21. McArthur J.C., Nance-Sproson T.E., Griffin D.E.et al. The diagnostic utility of elevation in cerebrospinal fluid of β2-microglobulin in HIV-1 dementia. Neurology. 42:1992;1707-1712.
22. Navia B., Jordan B.D., Price R.W. The AIDS dementia complex: I. Clinical features. Ann. Neurol. 19:1986;517-524.
23. Nokta M., Rossero R., Loesch K., Pollard R.B. Kinetics of tumor necrosis factor α and soluble TNFRII in HIV-1 infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea. AIDS Res. Hum. Retroviruses. 18:1997;1633-1638.
24. Nottet H.S.L.M., Gendelman H.E. Unraveling the neuroimmune mechanisms for HIV-1 encephalitis. Immunol. Today. 16:1995;441-448.
25. Portegies P., De Gans J., Lange J.M.A.et al. Declining incidence of AIDS dementia complex after the introduction of zidovudine treatment. Br. Med. J. 299:1989;819-821.
26. Portegies P., Godfried M.H., Hintzen R.Q.et al. Low levels of specific T cell activation marker CD 27 accompanied by elevated levels of markers for non-specific immune activation in the CSF of patients with AIDS dementia complex. J. Neuroimmunol. 48:1993;241-248.
27. Power C., Selnes O.A., Grim J.A., McArthur J.C. HIV dementia scale: a rapid screening test. J. Acquired Immune Defic. Syndr. Hum. Retroviruses. 8:1995;273-278.
28. Price R.W. Measuring the "viral load" in cerebrospinal fluid in HIV infection: window into brain infection? Ann. Neurol. 42:1997;675-678.
29. Schockmel G.A., Yerly S., Perrin L. Detection of low HIV-RNA levels in plasma. J. Acquired Immune Defic. Syndr. Hum. Retroviruses. 14:1997;179-183.
30. Schrager L.K., D'Souza P. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA. 280:1998;67-71.
31. Sippy B.D., Hofman F.M., Wallach D., Hinton D.R. Increased expression of tumor necrosis factor-α receptors in the brains of patients with AIDS. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 10:1995;511-521.
32. Stein D.S., Lyles R.H., Graham N.M.H.et al. Predicting clinical progression or death in subjects with early stage human immunodeficiency virus (HIV) infection: a comparative analysis of quantification of HIV RNA, soluble tumor necrosis factor type II receptors, neopterin, and β2-microglobulin. J. Infect. Dis. 176:1997;1161-1167.
33. Tozzi V., Narciso P., Galgani S.et al. Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex. AIDS. 7:1993;683-692.
34. Vullo V., Mastroianni C.M., Lichtner M., Mengoni F., Delia S. Increased cerebrospinal fluid levels of soluble receptors for tumour necrosis factor in HIV-infected patients with neurological disease. AIDS. 9:1995;1099-1100.
35. Weiss J.M., Downie S.A., Lyman W.D., Berman J.W. Astrocyte-derived monocyte-chemoattractant protein-1 directs the transmigration of leukocytes across a model of the human blood-brain barrier. J. Immunol. 161:1998;6896-6903.